Who shouldn't take PT-141?

What PT-141 is, in one paragraph

PT-141 is the research name for bremelanotide, a melanocortin receptor agonist. Instead of acting on blood flow the way erectile dysfunction pills do, it works on brain pathways involved in sexual desire.

One version is FDA-approved: Vyleesi, a self-injection for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) that causes marked distress and isn't explained by another condition, a medication or relationship problems. The label says it isn't for postmenopausal women, men, or enhancing sexual performance. Any other use is off-label. Compounded PT-141, including the PT-141 in HealifyMD's Triple Action Blend, is not FDA-approved. FDA does not review compounded drugs for safety, effectiveness or quality before they're dispensed, and a compounded preparation is not equivalent to Vyleesi.

The firm no's

These come straight from the FDA label and the clinical logic behind it. If one applies to you, PT-141 is off the table, at least for now.

• Uncontrolled high blood pressure. Bremelanotide raises blood pressure for several hours after a dose, so a pressure that's already too high is a contraindication.
• Known cardiovascular disease, such as prior heart attack, angina, stroke or heart failure. The label lists it as a contraindication and advises against use in people at high cardiovascular risk.
• Pregnancy, or the possibility of pregnancy without effective contraception. Animal data showed harm at high exposures, and the label advises stopping if pregnancy is suspected.
• A previous serious or intolerable reaction to bremelanotide.
• Taking oral naltrexone for alcohol or opioid use disorder. Bremelanotide sharply lowers naltrexone levels, which could undermine that treatment.

Why blood pressure gets so much attention

In the trials behind Vyleesi, blood pressure rose by up to about 6 mmHg systolic and 3 mmHg diastolic after a dose, peaking two to four hours later, while heart rate dropped by up to about 5 beats per minute. These shifts usually faded within 12 hours.

For a healthy person that's a small, temporary bump. For someone whose pressure is already high, or whose heart is already strained, it's a risk without a matching benefit. That's why your clinician will want more than one properly taken reading before prescribing. If your pressure is high but treatable, the usual order is to bring it under control first and revisit PT-141 afterward.

Skin darkening and nausea

About 1% of women in the placebo-controlled trials developed focal hyperpigmentation, meaning darker patches on the face, gums or breasts. It was more likely with darker skin and with daily dosing, and it didn't clear in everyone after stopping. If that possibility would be hard to live with, say so up front.

Nausea is the side effect most people notice. It affected about 40% of women in the trials, and 8% stopped because of it. It tends to ease after the first dose, but if you're already prone to nausea, factor that in.

When something else is likely to work better

Many people who ask about PT-141 have low desire with a clear, treatable driver. Treating the driver usually beats layering a desire drug on top of it. A clinician will usually look at these first:

• Pain, dryness or burning with sex, which is very common around and after menopause and often responds to local vaginal estrogen or other treatments.
• Medications known to dampen desire, including some antidepressants and blood pressure drugs.
• Depression, anxiety, exhaustion or broken sleep.
• Thyroid problems or other hormone issues that can show up on lab work.
• Relationship strain or stress, which no medication resolves.
• Erection problems in men. PT-141 isn't an erectile dysfunction treatment, and FDA-approved PDE5 inhibitors such as tadalafil are the established first option.

After menopause: a different evidence picture

The pivotal bremelanotide trials enrolled premenopausal women, so their results don't automatically carry over to women after menopause. For postmenopausal women with distressing low desire, a 2019 global consensus statement from major menopause and endocrine societies names testosterone at doses that keep levels in the premenopausal range as the one evidence-based hormonal option, after other contributors are addressed.

That doesn't mean PT-141 is never considered after menopause, but it's off-label and the trade-offs should be discussed plainly.

How HealifyMD screens before prescribing

Your online assessment asks about blood pressure, heart history, medications and supplements, pregnancy plans, and what exactly has changed in your sex life. Your clinician may ask for home blood pressure readings or labs before deciding. If PT-141 isn't a good fit, the visit still has value: you'll leave with a clearer sense of what's driving the problem and which options make sense.

At HealifyMD, PT-141 is available only as part of the compounded Triple Action Blend (tadalafil, oxytocin and PT-141), listed from $149/month. Pricing is confirmed at your eligibility review, there's no membership fee, and the eligibility check is free.